J. Goldman & CO LP Cor Medix Inc. Transaction History
J. Goldman & CO LP
- $3.53 Billion
- Q4 2024
A detailed history of J. Goldman & CO LP transactions in Cor Medix Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 457,320 shares of CRMD stock, worth $4.74 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
457,320
Previous 142,440
221.06%
Holding current value
$4.74 Million
Previous $1.15 Million
222.09%
% of portfolio
0.1%
Previous 0.04%
Shares
2 transactions
Others Institutions Holding CRMD
# of Institutions
135Shares Held
21.9MCall Options Held
599KPut Options Held
401K-
Black Rock Inc. New York, NY3.55MShares$36.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.38MShares$35 Million0.0% of portfolio
-
Paul Singer Elliott Investment Management L.P. | West Palm Beach, Fl2.87MShares$29.7 Million0.14% of portfolio
-
State Street Corp Boston, MA1.45MShares$15.1 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.39MShares$14.4 Million0.0% of portfolio
About CorMedix Inc.
- Ticker CRMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,208,200
- Market Cap $427M
- Description
- CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...